Project Grant W81XWH2210158

This Project Grant award for $267,298.00 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) will support research by the Dana-Farber Cancer Institute, Inc. (DFCI) to investigate targeting the CDK4/6 pathway as a potential therapeutic strategy for translocation renal cell carcinoma (TRCC), an aggressive and rare form of kidney cancer with no established standard of care. The project aims to test the efficacy of CDK4/6 inhibitors, alone or in combination with...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $546,349 to The University of Texas Southwestern Medical Center to investigate the molecular mechanisms by which the Von Hippel-Lindau (VHL) tumor suppressor regulates gene expression via N6-methyladenosine (m6A) modification in clear cell renal cell carcinoma (ccRCC). The research aims to determine how VHL interacts with the m6A enzymatic complex to control m6A-dependent gene expression,...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to investigate the role of the protein angiopoietin-like 4 (ANGPTL4) in clear cell renal cell carcinoma (ccRCC) and its potential as a therapeutic target. The 5-year, $371,905 award to the University of Florida aims to define ANGPTL4's functions in the ccRCC tumor microenvironment, assess the efficacy of combining anti-ANGPTL4 antibodies with immune...

This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $521,579 to The University of Texas Southwestern Medical Center to conduct research aimed at understanding the molecular mechanisms driving lung metastasis in clear cell renal cell carcinoma (CCRCC), a common and highly lethal form of kidney cancer. The key research objectives are to: 1) Characterize the functional role of the hepatic leukemia factor (HLF) gene in promoting CCRCC lung...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to elucidate the role of T cell ferroptosis and three-dimensional (3D) chromatin architecture in renal medullary carcinoma (RMC), a rare and aggressive form of kidney cancer that disproportionately affects young individuals of African descent, especially those with sickle cell disease. The $686,919 award to the University of Texas MD Anderson Cancer Center will fund research to: 1)...

This $396,061 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to assess the efficacy of a novel class of hypoxia-inducible factor (HIF) inhibitors as a potential treatment for renal cell carcinoma (RCC). The principal investigator has developed boron-based HIF inhibitors derived from the natural compound honokiol, which have demonstrated promising anti-angiogenic properties in vitro. This 2-year project aims to (1) determine...

This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $122,834 to Duke University to investigate how inhibiting the ABL kinase enzyme can sensitize small cell lung cancer (SCLC) cells to metabolic dysregulation, leading to cell death. The research aims to determine how ABL kinases mediate metabolic function, the mechanism of metabolic dysregulation following ABL inhibition, and the extent to which combining ABL kinase...

This $1,104,864 five-year federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to identify small molecule inhibitors that selectively bind the leucine zipper domain and disrupt the protein-protein interaction between the TFE3 chimeric proteins (TFE3-OS) and wild-type TFE3 (TFE3-WT). The key objectives are to optimize lead compounds like terfenaidine and fexofenadine, and screen for novel molecules that can inhibit TFE3 dimerization, with...

This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), provides $793,324 to the Beckman Research Institute of the City of Hope to develop selective small molecule inhibitors targeting the CYP8B1 enzyme for the treatment of hepatocellular carcinoma (HCC). The research aims to identify potent and specific CYP8B1 inhibitors through high-throughput screening, validate their potency and selectivity, and elucidate the...

This $693,880 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports the development of a novel cancer immunotherapy approach using engineered CD4+ T cells. The goal is to create CD4+ T cells that can target the tumor microenvironment and overcome resistance to current immune checkpoint inhibitor therapies. Key elements include: Identifying key molecules and immune cell targets of the engineered CD4+ T cells in preclinical cancer...